DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
Kodiak Sciences' investigational drugs tarcocimab and tabirafusp-ted met primary endpoints in the DAYBREAK trial for wet AMD, showing noninferior visual acuity gains compared to aflibercept. 54% of tarcocimab patients were on a 24-week dosing interval at year 1. The company plans to submit a BLA in Q4 2026.
How this was made
The 30-second read
Why it matters
The data represent a pivotal step toward regulatory approval, potentially expanding Kodiak's addressable market in wet AMD and diabetic retinal diseases.
Market read
Positive Phase 3 results are a material catalyst for Kodiak, likely influencing its stock and the ophthalmology biotech niche.
What to watch
Safety signals such as intraocular inflammation remain low, but long‑term efficacy and comparative advantage over higher‑dose aflibercept are still unknown.
Background
Kodiak Sciences (NASDAQ:KOD) focuses on antibody‑biopolymer conjugate platforms for ocular diseases. The DAYBREAK trial compares its candidates to the market‑leading anti‑VEGF aflibercept.
Ticker impact
Kodiak Sciences released topline Phase 3 DAYBREAK trial results showing its investigational drugs tarcocimab and tabirafusp‑ted met primary endpoints non‑inferior to aflibercept in wet AMD.
likely upward pressure as market prices in potential approval and market share gain
First disclosure of pivotal trial success for a late‑stage ophthalmology asset; biotech stocks typically react strongly to such data.
Market effects
May boost the broader ophthalmology/anti‑VEGF sector and increase interest in long‑acting biologics.
Primarily U.S. biotech market, with limited immediate effect on other regions.
Limited to investors tracking late‑stage biotech pipelines.
Counterpoint
If durability data does not translate to real‑world dosing intervals, the hype could fade.
Key entities
- CompanyKodiak Sciences
Biotech firm developing tarcocimab and tabirafusp‑ted for retinal diseases.
- DrugAflibercept
Market‑leading anti‑VEGF therapy used as comparator in the trial.
